Swing Trade NVAX: Medium Volatility Stock with 11.88% Returns
Swing Trader: Medium Volatility Stocks for Active Trading (TA&FA) Generates 11.88% for NVAX
The stock market offers a myriad of investment opportunities, but few are as exciting or potentially rewarding as active trading. As a case in point, Novavax Inc. (NVAX), a biotechnology company, has recently demonstrated an impressive return of 11.88% within the active trading segment, capitalizing on medium volatility.
On June 30, 2023, an intriguing development transpired in NVAX's technical analysis - the Moving Average Convergence Divergence (MACD) Histogram crossed above the signal line. The MACD is a momentum oscillator that can be instrumental in identifying potential buy and sell signals. When the MACD line crosses above the signal line, it is generally perceived as a bullish signal that suggests the potential for further stock price appreciation.
To understand the significance of this event, it is essential to analyze historical instances where NVAX's MACD line crossed the signal line. In 42 out of 43 instances, NVAX shares have continued to rise in the month following the positive MACD cross. This remarkably consistent pattern suggests a 90% probability of the stock's upward trend continuing.
By capitalizing on the medium volatility of NVAX's stock, Swing Trader, an active trading strategy focusing on Technical Analysis & Fundamental Analysis (TA&FA), has generated a commendable 11.88% return. This return is noteworthy and indicates that an active trading strategy combined with reliable technical indicators like the MACD can yield profitable outcomes.
NVAX is a potent example of how medium-volatility stocks can offer lucrative opportunities for active traders. With the MACD histogram crossing above the signal line and a historical pattern pointing to an upward trajectory, NVAX has presented an attractive trading opportunity with a demonstrated return of 11.88%. The Swing Trader strategy, focusing on TA&FA, has taken advantage of this medium-volatility stock to generate impressive gains, signifying the potential advantages of active trading strategies.
NVAX in downward trend: price may decline as a result of having broken its higher Bollinger Band on May 19, 2025
NVAX broke above its upper Bollinger Band on May 19, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In of the 40 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NVAX as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on June 11, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
NVAX moved above its 50-day moving average on May 19, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NVAX crossed bullishly above the 50-day moving average on May 23, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NVAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.950). P/E Ratio (2.524) is within average values for comparable stocks, (59.602). NVAX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.336). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.923) is also within normal values, averaging (257.570).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of novel recombinant vaccines
Industry Biotechnology
Advertisement